42
Participants
Start Date
January 22, 2016
Primary Completion Date
December 18, 2019
Study Completion Date
January 10, 2020
PRN1008
"Part A dosing was initiated administering 400 mg BID. Intrapatient dose adjustments (reductions and increases) were permitted based upon tolerability and clinical response with the maximum dose allowed up to 600 mg BID for 12 weeks.~Part B initial dosing was 400 mg QD for 2 weeks with dose escalation to 400 mg BID at the discretion of the Investigator for the purposes of investigating dose response and identifying the minimal efficacious dose of rilzabrutinib for 24 weeks."
Premier Specialists, Kogarah
Sinclair Dermatology, East Melbourne
Royal Melbourne, Dermatology Office, Melbourne
Hospital of Venereal and Skin Diseases A.Syggros, Athens
Clinical Hospital Osijek, Osijek
University Hospital of Larissa, Larissa
University General Hospital of Ioannina, Ioannina
Chaim Sheba Medical Center, Ramat Gan
Papageorgiou General Hospital of Thessaloniki, Thessaloniki
Tel Aviv Sourasky Medical Center, Tel Aviv
Rouen University Hospital, Rouen
Hôpital Avicenne, Bobigny
Klinichki Bolnicki Centar Zagreb, Zagreb
Principia Biopharma, a Sanofi Company
INDUSTRY